Evaluation of concentration procedures, sample pre-treatment, and storage condition for the detection of SARS-CoV-2 in wastewater.

Evaluation of concentration procedures, sample pre-treatment, and storage condition for the detection of SARS-CoV-2 in wastewater.

Publication date: Sep 21, 2023

Crucial information on the pandemic’s spread has been gathered by monitoring the trend of SARS-CoV-2 in wastewater. This surveillance has highlighted that the initial concentration is a critical step of the analytical procedure due to the low viral titer that may be present in this matrix. This paper presents the results of the evaluation of two different wastewater concentration protocols to determine the most efficient and cost-effective. The two methods tested were the following: (a) a biphasic separation system with PEG-dextran and (b) a PEG/NaCl precipitation protocol. Other aspects of the detection method were also investigated including the influence of storage temperature on virus recovery and the heat treatment of pasteurization, which aims to make samples safer for operators and the environment. The PEG/NaCl precipitation method was found to perform better than the biphasic separation system, allowing for more sensitive identification of the presence of the virus and the detection of a higher viral titer than that identified with the biphasic separation in all results. Storage of the samples at 4. 3+/-0. 2^0C for up to 3 weeks did not adversely affect the virus titer and the pasteurization pre-treatment increases operator safety and maintains the identification of the viral concentration.

Open Access PDF

Concepts Keywords
Pandemic Concentration methods
Pasteurization Pasteurization
Viral SARS-CoV-2
Wastewater Storage temperature
Weeks Wastewater
Wastewater-based epidemiology


Type Source Name
disease VO storage
disease VO titer
disease VO efficient
disease VO effective
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Dextran
disease VO protocol
drug DRUGBANK Tropicamide
disease VO time
disease MESH infection
disease VO effectiveness
disease VO immunization
disease VO Viruses
disease MESH hepatitis
disease MESH COVID 19
disease VO organization
disease MESH uncertainty
disease VO population
disease VO Iss
disease MESH emergency
disease MESH infectious diseases
disease VO document
disease VO efficiency
drug DRUGBANK Guanidine
drug DRUGBANK Silicon dioxide
disease VO volume
disease VO USA
disease IDO assay
disease VO ORF
disease VO inactivation
disease IDO process
drug DRUGBANK Penciclovir
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Water
drug DRUGBANK Coenzyme M
disease VO ANOVA
drug DRUGBANK Tretamine
drug DRUGBANK Aminosalicylic Acid
drug DRUGBANK Ademetionine
drug DRUGBANK Etoperidone
disease VO Env
pathway REACTOME Reproduction
disease VO Pal
drug DRUGBANK (S)-Des-Me-Ampa
disease MESH gastroenteritis
drug DRUGBANK Guanosine
disease MESH Piedra
drug DRUGBANK Hydroxyethyl Starch
drug DRUGBANK Trestolone
drug DRUGBANK Methyl isocyanate
disease VO vaccine
disease MESH polio

Original Article

(Visited 1 times, 1 visits today)